receptor antagonist (IC50
= 0.8 μ
M in LPA5
-RH7777 cells). Inhibits LPA-induced aggregation of isolated human platelets. Exhibits selectivity for LPA5
against 80 other screened targets.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Selective non-lipid modulator of LPA5 activity in human platelets.
Kozian et al.